For generics and biosimilars, more efficient production could be a major competitive advantage. The fact that we haven't seen breakthroughs in this area, despite clear financial motivation, suggests these are not easily solvable problems.
[0] https://www.fiercepharma.com/manufacturing/car-t-manufacturi...
The persistence of process-related challenges in both industries, despite significant financial motivation to solve them, underscores their complexity. This relates back to the "fractal no" concept from the original article, where each obstacle in cultured meat production is composed of many smaller obstacles. Importantly, monoclonal antibodies can sell for thousands of dollars per gram, orders of magnitude more than meat, yet even with this immense profit incentive, the pharmaceutical industry hasn't solved these bioprocessing issues. This suggests that cultured meat production, with its much lower profit margins, faces an overwhelming set of challenges,
[0] https://www.sciencedirect.com/science/article/abs/pii/S15700...